Published: September 15, 2020

The IRS has updated its website providing general guidance for taxpayers in the cannabis industry.The guidance does not announce any changes in law or enforcement but rather serves as a reminder of important limitations and obligations of cannabis companies:

. . . . . .

Published: August 21, 2020

On August 21, 2020, nearly two years after the passage of the Agriculture Improvement Act of 2018 (2018 Farm Bill), the Drug Enforcement Administration (DEA or the Agency) published an interim final rule that, according to the Agency, “merely conforms DEA’s regulations to the statutory amendments to the CSA [Controlled Substances Act] that have already taken effect.” 

. . . . . .

Published: July 24, 2020

It has been a busy summer for the cannabis and cannabis-derived products spaces. This month alone, the U.S. Food and Drug Administration (FDA or the Agency): (1) sent to the White House Office of Management and Budget (OMB) for review a “Cannabidiol Enforcement Policy” draft guidance; (2) announced the availability of another draft guidance, “Cannabis and Cannabis-Derived Compounds: Quality Considerations for Clinical Research”; and (3) made public its report to Congress, “Sampling Study of the Current Cannabidiol Marketplace to Determine the Extent That Products are Mislabeled or Adulterated.”

. . . . . .

Published: May 28, 2020

While Pennsylvania begins to rebound from the impacts of COVID-19, the restaurant industry across the state will begin to open its doors again for onsite dining. As the state progresses, there are limitations in place for restaurants in each of the reopening phases – red, yellow and green. Click here to learn more about what this might mean for your county or your business.

. . . . . .

Published: April 24, 2020

On April 23, 2020, the U.S. District Court for the District of Maryland granted the U.S. Food and Drug Administration’s (FDA or the Agency) request for an extension of the submission deadline for certain deemed tobacco product premarket review applications. FDA requested the extension on March 30, 2020, citing the “extraordinary circumstances” of the COVID-19 outbreak for the delay. The new deadline for applications for premarket review for deemed e-cigarettes, cigars, and other new tobacco products is September 9, 2020.

. . . . . .